{"id":"NCT01298765","sponsor":"BioDelivery Sciences International","briefTitle":"Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain","officialTitle":"A 52-Week, Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMAÂ® Buprenorphine in Subjects With Moderate to Severe Chronic Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2011-02-18","resultsPosted":"2018-08-07","lastUpdate":"2018-08-07"},"enrollment":302,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain","Low Back Pain","Osteoarthritis","Neuropathic Pain"],"interventions":[{"type":"DRUG","name":"BEMA Buprenorphine","otherNames":["buprenorphine buccal soluble film"]}],"arms":[{"label":"BEMA Buprenorphine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether BEMA Buprenorphine is safe in the treatment of chronic pain.","primaryOutcome":{"measure":"Change From Baseline in NRS Pain Intensity","timeFrame":"Baseline up to approximately Week 52","effectByArm":[{"arm":"BEMA Buproneorphine Overall","deltaMin":-0.24,"sd":1.803}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":302},"commonTop":["Nausea","Fatigue","Dizziness","Constipation","Irritability"]}}